Studies have confirmed that a variety of small molecule compounds and peptide drugs can restore the wild-type activity of p53 mutants by altering their spatial conformation and folding pattern, or by promoting the degradation of mutant p53 protein to inhibit its oncogenic activity and ultimately the tumor growth.12, 13, 14 Identifying the mutations in somatic TP53 may suggest new strategies to predict cancer development and progression and allow for the development of more effective medical treatments. The gene discussed is TP53; the disease is cancer.